This study investigated the safety and efficacy of orthokeratology in myopic children in Japan.
Prospective clinical trial.
This study enrolled myopic children aged 6–16 years with a spherical equivalent of −1.00 D to −4.00 D and astigmatism of −1.5 D or lower, whose parents could manage contact lens use and could provide written informed consent. The children were treated with orthokeratology lenses (BREATH-O CORRECT R, Universal View Co., Ltd.) for 3 years. Slit-lamp findings, visual acuity, intraocular pressure, subjective refraction, corneal topography, corneal endothelial cell density, corneal thickness, and axial length were regularly assessed.
This study included 96 eyes of 48 patients (average age, 10.7 ± 2.08 years). The average baseline spherical equivalent was −2.46 ± 0.97 D. The average baseline uncorrected visual acuity was 0.74 ± 0.32 logMAR, with significant improvement to −0.08 ± 0.18 logMAR at 4 weeks and 0.02 ± 0.21 logMAR at 3 years (both p < 0.001, Dunnett’s test). The average baseline corneal endothelial cell density was 3053 ± 181 cells/mm2 and 3028 ± 213 cells/mm2 at postoperative 3 years (p = 0.9933, Dunnett’s test). The average axial length was 24.70 ± 0.78 mm at baseline, 24.77 ± 0.80 mm at 12 weeks, and 25.32 ± 0.85 mm at 36 months. Although mild corneal epithelial disorders occurred in 18% of eyes, they were successfully treated with eye drops, enabling resumption of lens usage. No serious adverse events were observed.
Orthokeratology lens (BREATH-O CORRECT R) use in children demonstrated good efficacy and safety during 3 years of follow-up.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Nichols JJ, Marsich MM, Nguyen M, Marr JT, Bullimore MA. Overnight orthokeratology. Optom Vis Sci. 2000;77:252–9.
Rah MJ, Jackson JM, Jones LA, Marsden HJ, Bailey MD, Barr JT. Overnight orthokeratology: preliminary results of the Lenses and Overnight Orthokeratology (LOOK) study. Optom Vis Sci. 2002;79:598–605.
Hiraoka T, Ito T, Yamamoto T. Post-marketing surveillance of an orthokeratology lens—5-year follow-up results. J Jpn Contact Lens Soc. 2017;59:66–75.
Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) Study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53:7077–85.
Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012;53:5060–5.
Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. Br J Ophthalmol. 2009;93:1181–5.
Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53:3913–9.
Ohashi Y, Kanai J, Itoi M, Kinoshita S, Sawa M, Shimomura Y, et al. Guideline for Orthokeratology. J Jpn Contact Lens Soc. 2009;51:S29–31 (in Japanese).
Murakami A, Yoshino K, Ueda K, Goto T, Shiraishi A, Hieda O, et al. Guideline for Orthokeratology, 2nd Ed. J Jpn Ophthalmol Soc. 2017;121:936–8 (in Japanese).
Voluntary Industry Guideline for clinical evaluation of contact lenses. Japan Contact Lens Soc. August 1, 2009.
Tokoro K, Suzuki K. Change in ocular refractive components and development of myopia during seven years. Jpn J Ophthalmol. 1969;13:27–34.
Zadnik K, Mutti DO, Mitchell GL, Jones LA, Burr D, Moeschberger ML. Normal eye growth in emmetropic school children. Optom Vis Sci. 2004;81:819–28.
The authors thank Xiaodong Zheng, MD, PhD (Ehime University School of Medicine) for his invaluable advice and assistance on this paper.
Conflict of interest
T. Goto, None; A. Shiraishi, None; Y. Ohashi, None; K. Negishi, Grant, Financial support (RE Medical, Bausch + Lomb, Wakamoto, TORAY, Universal View, Fuji Xerox), Grant, Honorarium for Lecturing, Financial support (HOYA, AMO, Kowa, Senju, Santen, Alcon), Grant, Honorarium for Lecturing (M3, Chuo Sangio, Otsuka, Qualitas, NIDEK), Tsubota Laboratory and the author are applicant for the patent of potential products for myopia suppression; K. Tsubota, Executive (Tsubota Laboratory); Y. Nakamura, None; O. Hieda, None; C. Sotozono, Lecture fee (Otsuka, Santen, Senju, TOA); S. Kinoshita, Honorarium for Lecturing, Consulting (Santen, Senju, Otsuka), Honorarium for Lecturing (Kowa), Senju and the author own the patent for the use of ROCK inhibitor. CorneaGen and the author own the patent for the use of ROCK inhibitor. Santen and the author own the patent for glaucoma-related genes. Sysmex and the author are applicants for the patent for SJS-related genes.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Corresponding Author: Tomoko Goto
About this article
Cite this article
Goto, T., Shiraishi, A., Ohashi, Y. et al. A multicenter clinical trial of orthokeratology in school-aged children and adolescents in Japan. Jpn J Ophthalmol (2021). https://doi.org/10.1007/s10384-021-00842-8
- School-aged children
- Axial length